Physician profile
Ashwin Kishtagari
NPI 1437565652
$88,200.70
in general payments reported to CMS, 2019-2025
24 companies · $23K in 2025
The $23K reported for 2025 was more than what 86% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $95.00 · 2022: $9,127 · 2023: $28K · 2024: $27K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,995 · Food and Beverage: $7,768 · Honoraria: $7,521 · Travel and Lodging: $6,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,736.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,749.95 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,995.00 |
| Food and Beverage | $7,767.74 |
| Honoraria | $7,521.00 |
| Travel and Lodging | $6,809.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $28,328.76 | 2022-2023 | Vonjo |
| Sobi, INC | $23,988.49 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $7,262.82 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Incyte Corporation | $6,883.86 | 2024 | Jakafi |
| Geron Corporation | $5,744.22 | 2025 | Imetelstat |
| Morphosys, US INC. | $3,579.68 | 2023 | |
| Syndax Pharmaceuticals, INC. | $2,393.42 | 2025 | Revuforj |
| Novartis Pharmaceuticals Corporation | $2,274.48 | 2023-2025 | |
| Blueprint Medicines Corporation | $2,184.43 | 2025 | |
| Servier Pharmaceuticals LLC | $1,680.00 | 2023 | |
| Siemens Medical Solutions USA, INC. | $1,035.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $850.00 | 2025 | |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Vertex Pharmaceuticals Incorporated | $367.00 | 2022 | |
| Abbvie INC. | $249.22 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $198.00 | 2019 | |
| Amgen INC. | $159.99 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $121.82 | 2023 | Empaveli |
| Alexion Pharmaceuticals, INC. | $113.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2019 | |
| Celgene Corporation | $61.05 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Kishtagari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.